Vanguard Investments Australia
BCRX icon

Vanguard Investments Australia’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vanguard Investments Australia’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$519K Hold
51,880
– – ﹤0.01% 1641
2026
Q1 		$494K Buy
+51,880
New +$403K ﹤0.01% 1575

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vanguard Investments Australia's BCRX Position: Q2 2026 in Review

Vanguard Investments Australia held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 51,880 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Vanguard Investments Australia first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vanguard Investments Australia held 51,880 shares of BioCryst Pharmaceuticals worth $519K as of Q2 2026.
  • Vanguard Investments Australia left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1641 holding.
  • Vanguard Investments Australia first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.